Perspective Confidentiality Disclosure Reliability Courtesy
Natural orifice transluminal endoscopic surgery or NOTES refers to the conduct of minimally invasive surgery through natural orifices (like the mouth or the vagina or the nose). … READ MORE …
Filed under: Management, Treatment, Uncategorized | Tagged: NOTES, radical prosatectomy, minimally invasive | Leave a Comment »
A media release from New York University Langone Medical Center, issued yesterday, has announced the initiation of a multi-center, Phase I/II clinical trial of vascular-targeted photodynamic therapy (VTP) in men with localized prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: localized, vascular-targeted photodynamic therapy, WST11, photosensitizer | Leave a Comment »
Traditional forms of hormone therapy for prostate cancer are based on the idea that you reduce testosterone levels as low as you can so as to stop the ability of testosterone and its metabolites (e.g., dihydrotestosterone) to stimulate growth of prostatic tissues — including prostate cancer cells. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: therapy, androgen, castration-resistant, CRPC, bipolar | Leave a Comment »
As an adjunct to the 12-year outcome data provided in the immediately preceding report come data from Canada that compare actual 5-year brachytherapy outcome data to predicted 5-year surgical outcome data for the same patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: surgery, brachytherapy, outcome, comparison | 2 Comments »
The long-term data on outcomes after first-line treatment with brachytherapy for localized prostate cancer are becoming increasingly compelling, and studies have also suggested strongly that quality of life data are better after brachytherapy than after other forms of treatment. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, long-term, outcome, seed implantation | 6 Comments »
There is a good deal of media noise today about a newly published study in Archives of Internal Medicine. The study addresses the “risk profiles and treatment patterns” of US prostate cancer patients diagnosed with a PSA of ≤ 4.0 ng/ml.” … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, PSA, Treatment, low risk, over-treatment | 5 Comments »
According to a media release issued yesterday by the University of North Carolina Lineberger Cancer Center, researchers at this institution have been awarded the first contract we are aware of ”to conduct comparative effectiveness research comparing different management strategies for localized prostate cancer.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: quality of life, localized, outcome, comparative effectiveness | 3 Comments »
DoD PCRP stands for the Congressionally mandated Department of Defense Prostate Cancer Research Program — and it is the only US government-sponsored initiative that dedicates funding specifically to prostate cancer research. (Similar DoD cancer programs provide dedicated funding for research into breast, lung, colon, and ovarian cancers.) … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: research, funding, PCRP, DoD | 1 Comment »
There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:
Filed under: Drugs in development, Management, Risk, Treatment | Tagged: angiogenesis, calcitriol, cryotherapy, GTI-2040, hybrid, imaging, statin, synergy | Leave a Comment »
The conclusion of a meta-analysis of data from 12 prior studies suggests that drinking coffee has no significant impact on risk for prostate cancer. This news will no doubt come as a great relief to the good people at Starbucks! … READ MORE …
Filed under: Diagnosis, Risk | Tagged: coffee | Leave a Comment »
Over the past few months, the US Food and Drug Administration (FDA) has issued a slew of letters to companies marketing tests designed to provide consumers with information about their genetic profile and their risks for certain types of disease. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genetics, risk, test, genes | 4 Comments »
Sometimes it is difficult to decide who to be more irritated at … the researchers who publish highly dubious data, the PR people who send out the breathless press releases touting the highly dubious data, or the media that actually publish these data as if they are correct and/or important. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: relative, finger, length | 1 Comment »
PSA doubling time or PSADT is a valuable prognostic factor in assessing the need for second- or even third-line treatment in men with biochemical progression of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: calculator, on-line, PSA doubling time, PSADT | 5 Comments »
There has long been discussion about the theoretical possibility of suspending androgen deprivation therapy (ADT) in men with a long-term, stable response to this form of hormonal therapy. However, there have been few long-term data reported on responses to this strategy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, outcome, ADT, cessation, stable disease | 5 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site